LAVA Therapeutics NV

LAVA Therapeutics NV — Investor Presentation (August 2023)

43 slides from LAVA Therapeutics NV's investor presentation, Aug 15, 2023

  1. Slide 1: Gamma-delta T cell engagers for the development of next-generation cancer therapeutics

    Gamma-delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation August 2023

  2. Slide 2: Legal Disclosure: Forward-looking Statements

    Legal Disclosure: Forward-looking Statements 2 This presentation contains statements that constitute forward-looking statements. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as “anticipate,” “believe,” “could,” “expe

  3. Slide 3: Pioneering Next-Generation Cancer Therapeutics

    Pioneering Next-Generation Cancer Therapeutics ©LAVA Therapeutics 2023 3 • Bispecific antibody platform to engage V9V2 T cells for highly specific tumor cell killing – Leverage the unique quality of V9V2 T cells to selectively kill tumor cells – Gammabody® combines potent tumor cell killing with

  4. Slide 4: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications

    MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer Gammabody® Pipeline: Potential in Hematological and Solid Tumor Indications 4 ©LAV

  5. Slide 5: Team Led by Experienced Leaders in the Biotech and Pharma Field

    Ton Adang, PhD CDO • Vast experience in drug development • Extensive experience in product discovery and project management (e.g., KEYTRUDA) HansvanderVliet,MD,PhD CSO • Inventor of LAVA’s gamma-delta T cell engager platform • Medical oncologist, extensive experience in preclinical and clinical rese

  6. Slide 6: LAVA's Proprietary Gammabody Platform: Bispecific Gamma-Delta T Cell Engagers

    LAVA’s Proprietary Gammabody® Platform Bispecific Gamma-Delta T Cell Engagers

  7. Slide 7: Enthusiasm for Bispecific T Cell Engagers

    glofitamab (DLBCL) Approved in the US in 2023 Source: The Antibody Society Data as of May 31, 2023 ©LAVA Therapeutics 2023 7 • High expectations for T cell bispecific therapies driving significant development • 200+ bispecific antibodies in the clinic, 6 bsTCEs currently approved Enthusiasm for Bisp

  8. Slide 8: Enthusiasm for Bispecific T Cell Engagers: Narrow Therapeutic Window

    • High expectations for targeted T cell therapies in cancer, but often: – Narrow therapeutic window: – Cytokine Release Syndrome – On-target/off-tumor-related toxicities – Activates immunosuppressive T cells – Sporadic efficacy in solid tumors therapeutic window therapeutic effect toxic effect ©LAVA

  9. Slide 9: Strategies for Widening the Therapeutic Window

    • Selecting ‘tumor-specific’ targets • Step-dosing / subcutaneous dosing • Decreasing affinity for T cells • Masking/site-specific activation • Recruiting alternative effector cells • Address only narrow target range, and/or • Cumbersome, and/or • Strongly decrease potency ©LAVA Therapeutics 2023 9

  10. Slide 10: Bispecific γδ T cell-engagers harness innate and adaptive immunity

    Bispecific  T cell-engagers aim to harness innate & adaptive immunity • Largest -T cell subset in blood: (~90-95% of total γδ-T cells) • Natural ability to recognize and kill tumor cells • Presence of  T cells associated with improved outcomes in cancer patients • Recognize tumors through phos

  11. Slide 11: Systemic Activation of Vγ9Vδ2 T Cells Showed Promise

    Systemic Activation of V9V2 T Cells Showed Promise • Systemic activation and proliferation via treatment with V9V2 T cell-based therapy (synthetic phosphoantigens (BrHPP) / aminobisphosphonates ± low-dose IL-2) Early attempts with V9V2 T cell-based therapy showed promise, but efficacy may have

  12. Slide 12: Off-the-Shelf Gammabody Platform: Directing Vγ9Vδ2 T Cells to Cancer Cells

    Off-the-Shelf Gammabody® Platform: Designed to Enhance Innate Tumor Recognition by Directing V9V2 T Cells to the Cancer Cells LAVA’s Gammabody® designed ti directs V9V2 T cells to tumors to induce direct tumor cell killing with high potency and has the potential to trigger a cascade of anti-canc

  13. Slide 13: Cascade of Anti-Cancer Responses – Potential Favorable Therapeutic Window

    Cascade of Anti-Cancer Responses – Potential Translation to Favorable Therapeutic Window Efficacy: • Potent killing of cancer cells (EC50s in the low picomolar range) • No co-activation of immune-suppressive Tregs which dampen antitumor efficacy of cytotoxic T cells • Orchestrate innate and adaptive

  14. Slide 14: Expansion & Cascade Response Without Treg Activation in Preclinical Models

    Gammabody® can induce robust gamma delta T cell expansion and can amplify the anti-tumor immune response via downstream activation of other immune cells while avoiding co-activation of immunosuppressive T cells such as Tregs Expansion Cascade Response No Treg Activation Gammabody™ - Mediated Expansi

  15. Slide 15: Gammabody Can Selectively Kill Cancer Cells While Sparing Healthy Cells

    • 2:1 ratio ( T cells : Target cells) • Similar CD20 expression levels on C1R neo and B-cells Preferential killing of cancer versus healthy cells demonstrated in vitro and ex vivo; May prevent on-target/off-tumor mediated toxicity and allow for targeting of widely expressed tumor associated antige

  16. Slide 16: LAVA-1207 Gammabody Targeting PSMA for the Treatment of mCRPC

    LAVA-1207 Gammabody® Designed to Activate V9V2 T Cells by Targeting PSMA for the Treatment of mCRPC

  17. Slide 17: LAVA-1207: PSMA-targeting Gammabody for Prostate Cancer

    LAVA-1207: PSMA-targeting Gammabody® for Prostate Cancer Format • Contains a Fc domain for extended plasma half-life; silenced to avoid off-target T cell activation • Small size (compared to regular IgG antibodies) to facilitate tumor penetration Mechanism of Action • Specifically directs V9V2 T c

  18. Slide 18: Prostate Cancer Epidemiology

    18 Prostate Cancer Epidemiology Cancer.Net® FMI (Future Market Insights) ©LAVA Therapeutics 2023 Prostate Cancer − Most frequently diagnosed cancer in males (estimated 288,300 in the United States in 2023) − Second leading cause of cancer deaths in males (estimated 34,700 in the United States in 202

  19. Slide 19: mCRPC – Existing Treatment Options

    19 mCRPC – Existing Treatment Options ©LAVA Therapeutics 2023 PARPi’s monotherapy or in combination in BRCAmut +ve 1L (~30,000) Docetaxel or androgen receptor pathway inhibitor (ARPI) (abiraterone, enzalutamide) 2L (~20,000) Docetaxel or ARPI (depending on prior treatment) 3L+ (~10,000) Cabazitaxel,

  20. Slide 20: PSMA-Selected Targeted Agents Landscape

    20 PSMA-Selected Targeted Agents Landscape ©LAVA Therapeutics 2023 PSMA-targeted radioligands Drug Study Patient Population N Clinical Results Common Adverse Events Current Status 177Lu-PSMA vs BSOC VISION mCRPC post 1+ ARPI and 1+ taxane 551 vs 280 ORR: 30 vs 2% PSA50: 46 vs 7 % Median OS: 15.3 vs

  21. Slide 21: LAVA-1207 – Phase 1/2a Study Design

    LAVA-1207 – Phase1/2a Study Design 21 • Dose escalation in patients with mCRPC (EudraCT 2021-001789-39; NCT05369000) • Primary objectives: investigate safety and tolerability of LAVA-1207 • Secondary objectives: evaluate PK, PD, immunogenicity and preliminary signs of antitumor activity • LAVA-1207

  22. Slide 22: LAVA-1207 – Patient Baseline Characteristics

    LAVA-1207 – Patient Baseline Characteristics 22 N=20 ASCO GU 2023 abstract #153 Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 Data cut-off date: 8 Dec 2022 Patient Baseline Characteristics Age, median (range) 68 (51-76) Years since diagnosis, median (range) 9 (3-21) Prior systemic ther

  23. Slide 23: LAVA-1207 – Time on Treatment

    LAVA-1207 – Time on Treatment ASCO GU 2023 abstract #153 Data on file: LAVA Therapeutics N.V ©LAVA Therapeutics 2023 23 • Patients were treated with LAVA-1207 with treatment duration ranging from 4 to 38 weeks • Subsequent to ASCO GU 2023 presentation, LAVA has completed recruitment for dose levels

  24. Slide 24: LAVA-1207 – Initial Phase 1 Data - Safety

    0 20 40 60 Fatigue Fever Nausea Anemia Constipation Back pain Pain AST increase Alkaline phosphatase increase Vomiting Anorexia Fall Tumor pain Hematuria Tingling Infusion related reaction Diarrhea Dry mouth Dyspepsia Dyspnea Edema Cytokine release syndrome Chills Flu-like symptoms Hot flashes Hyper

  25. Slide 25: LAVA-1207 – Pharmacokinetics

    LAVA-1207 – Pharmacokinetics • Pharmacokinetics of LAVA-1207 appears linear • Data cut-off date: 8 Dec 2022 25 0 24 48 72 96 120 144 168 1,000 10,000 Dose level 4 Time since infusion start (h) LAVA-1207 (ng/L) 5000 N303 N304 N305 0 24 48 72 96 120 144 168 1,000 10,000 Dose level 5 Time since infusio

  26. Slide 26: LAVA-1207 – Pharmacodynamics

    LAVA-1207 – Pharmacodynamics • Pharmacodynamics reflect changes expected as per MoA − Pronounced drop in V9V2-T cell frequency 2 hr after dosing, suggesting V9V2-T cell re-distribution, with subsequent recovery − V9V2-T cell activation markers (CD25 and CD69) upregulated following dosing − Rec

  27. Slide 27: LAVA-1207 Preliminary Signs of Anti-Tumor Activity

    LAVA-1207 27 Preliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in 8 out of 14 evaluable patients at week 8 and PSA levels stabilizing or decreasing in heavily pre-treated patients 27 Patient N304 – 40 g • Largest overall decrease in PSA was 61% (46% vs baseli

  28. Slide 28: Addition of IL-2 Supports Gammabody Induced Vγ9Vδ2 T Cell Proliferation

    28 T cell TCR triggering: upregulation of high-affinity IL-2R Addition of IL-2 supports Gammabody® induced Vγ9Vδ2 T cell proliferation IL-2 binds to IL-2R complex and promotes proliferation IL-2 supports Gammabody® induced expansion of V9V2 T cells ©LAVA Therapeutics 2023 IL-2 immunomodulation has

  29. Slide 29: Summary of Initial Phase Data

    Summary of Initial Phase 1 Data • LAVA-1207 reached a dose of 120 g (starting dose 1.5 g) without the occurrence of high-grade (>2) CRS or DLTs in therapy refractory mCRPC patients – Frequency and severity of AEs do not appear to be dose-dependent – Most observed AEs were not suspected to be relat

  30. Slide 30: LAVA-051 Targets CD1d for the Potential Treatment of CLL, MM & AML

    LAVA-051 Targets CD1d to Activate V 9V2 T Cells and iNKT Cells for the Potential Treatment of CLL, MM & AML

  31. Slide 31: LAVA-051: First-in-Class Gammabody Targeting CD1d

    Format • Humanized bispecific single domain antibody (bsVHH) of 27kDa ‒ Short plasma half-life, prolonged functional half-life through high affinity TCR binding Mechanism of Action • Engages V9V2 T cells to mediate potent killing of CD1d-expressing tumor cells – CD1d is expressed on tumor cells in

  32. Slide 32: LAVA-051 – Phase 1 Data Confirms MoA in Patients with MM and CLL

    02 4 6 8 0.0 0.2 0.4 0.6 0.8 1.0 20 40 60 80 100 120 V9V2 T cell frequency Cohort 2 pt 02-001 Treatment days % of CD3+ 0 2 4 6 8 12 0 20 40 60V9V2 T cell activation Cohort 2 pt 02-001 Treatment days % CD25+ 0 2 4 6 8 0 5 10 15 20 25 V9V2 T cell RO Treatment days %RO 3 μg 15 μg 45 μg (1 pt) 32

  33. Slide 33: LAVA-051 – Potential Signs of Activity

    LAVA-051 – Potential Signs of Activity CLL • Patient with R/R CLL (15 g) • Temporary enlargement and tenderness of several involved lymph nodes accompanied by grade 2 fever during Cycle 1 ‒ Resembled a tumor-flare reaction, as reported in CLL with lenalidomide • Patient assessed as having stable di

  34. Slide 34: LAVA-051 – Preliminary Conclusions

    LAVA-051 – Preliminary Conclusions • Phase 1 trial supports MoA and safety of the Gammabody® platform − Binding and activation of V9V2 T cells and associated effects on tumors • Trial for relapsed or refractory CLL and MM to be discontinued − Trial ended due to challenging enrollment; highly compe

  35. Slide 35: SGN-EGFRd2 (LAVA-1223) – Licensed to Seagen

    SGN-EGFRd2 (LAVA-1223) – Licensed to Seagen Gammabody® for the treatment of EGFR-expressing solid tumors

  36. Slide 36: SGN-EGFRd2 (LAVA-1223) – EGFR-Targeting Gammabody

    SGN-EGFRd2 (LAVA-1223) – EGFR-Targeting Gammabody® Format • Gammabody® containing a silenced Fc domain Mechanism of Action • Induces preferential lysis of EGFR-expressing tumor cells while relatively sparing EGFR-expressing normal cells Status • IND cleared • Phase 1 Study in Advanced Solid Tumors e

  37. Slide 37: Janssen Collaboration

    Janssen Collaboration Lead Candidate in Development Toward Clinic

  38. Slide 38: Janssen Collaboration

    Janssen Collaboration 38 • Lead candidate, aimed at an undisclosed tumor-associated antigen, has been chosen for further development toward clinical studies − In May 2020, LAVA entered into a research collaboration and license agreement with Janssen for the discovery and development of a novel bispe

  39. Slide 39: CD123 Targeting Gammabody for Hematologic Malignancies: LAVA-1266

    CD123 Targeting Gammabody® for the Treatment of Hematologic Malignancies LAVA-1266

  40. Slide 40: LAVA-1266: CD123-Targeting Gammabody

    • In Development for Treating Hematological Malignancies • Mechanism of Action − Induces preferential lysis of CD123-expressing tumor cells while relatively sparing CD123-expressing normal cells • CD123 is overexpressed in a wide range of hematological malignancies LAVA-1266: CD123-Targeting Gammabo

  41. Slide 41: Anticipated Milestones & Recent Updates

    Anticipated Milestones & Recent Updates

  42. Slide 42: Gammabody Pipeline: Potential in Hematological and Solid Tumor Indications

    MM: multiple myeloma CLL: chronic lymphocytic leukemia AML: acute myeloid leukemia PSMA: prostate-specific membrane antigen EGFR: epidermal growth factor receptor mCRPC: metastatic castration-resistant prostate cancer Gammabody® Pipeline: Potential in Hematological and Solid Tumor Indications 42 ©LA

  43. Slide 43: Gamma-delta T cell engagers for the development of next-generation cancer therapeutics

    Gamma-delta T cell engagers for the development of next-generation cancer therapeutics Corporate Presentation August 2023

LAVA Therapeutics — Investor Presentation (August 2023) on 6ix